Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review

Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Ansari, Jawaher, Batubara, Enas, Ali, Muhammad, Farrag, Ashraf, Bashir, Farhat, Farghaly, Hussein R., Ali, Arwa M., Shaukat, Arif
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2018
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030992/
https://ncbi.nlm.nih.gov/pubmed/29977544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados